35205 Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and PSO-2 trials
Augustin M, Strober B, Armstrong A, Beaumont J, Pham T, Hudgens S, Zhuo J, Becker B, Banerjee S, Kisa R, Papp K. 35205 Deucravacitinib improves Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and PSO-2 trials. Journal Of The American Academy Of Dermatology 2022, 87: ab156. DOI: 10.1016/j.jaad.2022.06.656.Peer-Reviewed Original Research